DT&CRO Co. Ltd.

383930 · KQ · Healthcare / Biotechnology

2,065.00KRW+5.00 (+0.24%)

Price History

Full chart

Market Stats

Previous Close2,060.00

Open2,020.00

Day Range2,010.00 – 2,120.00

52-Week Range1,430.00 – 4,115.00

Volume20.95K

Market Cap25.22B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta1.18

50-Day Avg1,691.26

200-Day Avg2,468.53

About

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
Employees0
Headquarters28, Baengnyeong-ro 20beon-gil, Yongin-si, South Korea, 17042, Korea
Websitehttps://www.dtncro.com

Financials

Income Statement

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	32.75B	44.01B	26.59B	35.97B	47.75B
Growth (%)	-	+34.38%	-39.59%	+35.30%	+32.74%
Cost of Revenue	25.21B	35.03B	33.30B	39.07B	45.14B
Gross Profit	7.54B	8.98B	-6.72B	-3.10B	2.61B
Gross Margin	23.03%	20.40%	-25.26%	-8.61%	5.47%
Operating Expense	2.63B	3.68B	6.46B	8.20B	8.35B
Operating Income	4.91B	5.29B	-13.17B	-11.30B	-5.74B
Operating Margin	14.98%	12.03%	-49.54%	-31.40%	-12.03%
EBITDA	-	8.62B	-12.05B	4.94B	6.13B
EBITDA Margin	-	19.59%	-45.33%	13.73%	12.84%
Net Income	4.33B	5.26B	-16.64B	-2.00B	-2.78B
Net Income Margin	13.21%	11.94%	-62.57%	-5.56%	-5.82%
Interest Expense	119.40M	61.53M	147.81M	1.38B	2.30B
Interest Expense % of Total Revenue	0.36%	0.14%	0.56%	3.85%	4.82%

Balance Sheet

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	32.89B	64.53B	59.85B	81.09B	90.38B
Total Liabilities	14.88B	18.21B	28.17B	52.42B	65.29B
Total Equity	18.01B	46.32B	31.68B	28.67B	25.09B
Cash	7.07B	20.50B	5.05B	4.67B	335.42M
Net Debt	-	-	9.86B	21.65B	33.93B

Cash Flow

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	6.06B	5.01B	-3.52B	-6.40B	-2.26B
Investing Cash Flow	-	-14.89B	-22.78B	-18.70B	-
Financing Cash Flow	-	23.31B	10.85B	24.71B	-
Capital Expenditure	8.05B	14.87B	17.06B	19.29B	11.92B
Free Cash Flow	-2.00B	-9.86B	-20.57B	-25.69B	-14.18B
FCF to OCF	-32.95%	-196.95%	585.20%	401.64%	628.13%

Earnings

Report Date	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	68.13	-85.44	-217.35	-1004.50	-363.93	-409.48	-143.32	759.04	-334.64	-122.38	-153.01	48.83	-1077.73	-320.99
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap25.22B

Enterprise Value60.48B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.51

Price / Book2.87

Revenue (TTM)49.00B

Gross Profit (TTM)2.25B

EBITDA-3.86B

Profit Margin-34.88%

Operating Margin-58.10%

Return on Equity-105.09%

Return on Assets-7.52%

Shares Outstanding12.78M

Shares Float8.85M

Beta1.18

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Mar 9, 20232:1